Project Grant K08AI185298
Award Date
7/16/25
Completion Date
6/30/30
Dollars Obligated
$198K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $473,937 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel point-of-care liquid biopsy for early detection of sepsis-associated organ damage. The project aims to optimize a microfluidic enrichment and digital PCR assay to detect tissue-derived circulating rare cells...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
The University of Rochester was awarded a $462,000 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate how the microbiome in healthy human blood differentially "primes" or trains neutrophils, leading to varied inflammatory responses during sepsis. The research aims to elucidate the mechanisms underlying this microbiome-mediated immune...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $479,249 to Washington University to conduct research on the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The research aims to understand how neutrophil A20 signaling contributes to organ damage in sepsis, utilizing biochemical, cell biological, and intravital imaging...
This federal Project Grant award, valued at $472,210.00 and effective June 23, 2025 through May 31, 2027, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by the University of Massachusetts Medical School to investigate the spatiotemporal relationship between CD4+ T resident memory cells and neutrophil recruitment in the lungs during pneumonia in experienced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $721,728 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Regents of the University of Michigan. The grant aims to investigate how persistent viral infections, such as human cytomegalovirus and Epstein-Barr virus, may worsen clinical outcomes and decrease response to immunomodulatory therapies in pediatric patients with sepsis. The research project will leverage...
This Project Grant award of $460,625 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the mechanisms by which post-sepsis exercise therapy can regulate CD4 T cell immunity and protect against secondary Pseudomonas aeruginosa infections in sepsis survivors. The 2-year study, which commenced on July 7, 2025, will be conducted by the Feinstein Institutes for Medical...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...
This Project Grant award, valued at $735,078, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports a 5-year research project to investigate the molecular mechanisms of innate immune memory in humans, with a focus on understanding the epigenetic determinants that enable long-lasting "trained immunity" in myeloid and lymphoid progenitor cells. The...